Compare Manchester United PLC (MANU) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs State Street SPDR S&P Biotech ETF — how do they compare? Manchester United PLC trades at $22.23 (market cap $3.80B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Manchester United PLC pays a 1.26% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| MANU | XBI | |
|---|---|---|
Market Cap | $3.80B | — |
Sector | Media | Broad Market / Factor |
52-Week High | $23.53 | $164.28 |
52-Week Low | $15.10 | $86.92 |
Enterprise Value | $4.74B | — |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $22.88, up 5.44% on the day, with a bearish technical signal. The company reported a net loss of $33.02M for 2025, though revenue grew to $666.51M. Recent news highlights the acquisition of land for a new 100,000-seat stadium as a significant long-term de-risking milestone. Cash flow from operations remains positive at $72.70M, but negative profitability metrics and high debt levels persist.
The outlook is mixed; stadium development and Champions League qualification offer growth catalysts, but consistent net losses and weak margins pose fundamental risks. Analyst consensus is neutral with a 60% hold rating. The stock's trajectory hinges on successful execution of cost reductions and capitalizing on new revenue streams from the stadium project.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
